Question

A 44-year-old woman (BMI 31 kg/m²) with type 2 diabetes and prior NSTEMI asks about optimising glucose-lowering therapy; A1c is 7.6% on metformin. eGFR is 80 mL/min/1.73 m². What agent class provides cardiovascular benefit beyond glycaemic control?

Accepted Answer

GLP-1 receptor agonist with proven CV benefit

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

Thiazolidinedione

Answer

Basal human insulin

Practice question

A 44-year-old woman (BMI 31 kg/m²) with type 2 diabetes and prior NSTEMI asks about optimising glucose-lowering therapy; A1c is 7.6% on metformin. eGFR is 80 mL/min/1.73 m². What agent class provides cardiovascular benefit beyond glycaemic control?